Author:
Girard Bethany,Baum-Jones Elisabeth,Best Rebecca L.,Campbell Thomas W.,Coupart Jack,Dangerfield Kyla,Dhal Abhilash,Jhatro Michael,Martinez Brian,Reifert Jack,Shon John,Zhang Minlu,Waitz Rebecca,Chalkias Spyros,Edwards Darin K.,Maglinao Maha,Paris Robert,Pajon Rolando
Abstract
BackgroundCharacterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines.MethodsThis study investigated the distinct antibody epitopes toward the SARS-CoV-2 spike (S) protein targeted after a two-dose primary series of mRNA-1273 followed by a booster dose of mRNA-1273 or a variant-updated vaccine among serum samples from clinical trial adult participants.ResultsMultiple S-specific epitopes were targeted after primary vaccination; while signal decreased over time, a booster dose after >6 months largely revived waning antibody signals. Epitope identity also changed after booster vaccination in some subjects, with four new S-specific epitopes detected with stronger signals after boosting than with primary vaccination. Notably, the strength of antibody responses after booster vaccination differed by the exact vaccine formulation, with variant-updated mRNA-1273.211 and mRNA-1273.617.2 booster formulations inducing significantly stronger S-specific signals than a mRNA-1273 booster.ConclusionOverall, these results identify key S-specific epitopes targeted by antibodies induced by mRNA-1273 primary and variant-updated booster vaccination.
Reference35 articles.
1. WHO coronavirus (COVID-19) dashboard2023
2. SPIKEVAXPackage Insert.2022
3. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021
4. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness;Corbett;Nature,2020
5. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States2022